<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The success of anticancer chemotherapy relies at least in part on the induction of an immune response against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> growing on mice that lack the pattern recognition receptor TLR4 or the purinergic receptor P2RX7 fail to respond to chemotherapy with anthracyclins or <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in conditions in which the same <z:hpo ids='HP_0002664'>neoplasms</z:hpo> growing on immunocompetent mice would do so </plain></SENT>
<SENT sid="2" pm="."><plain>Similarly, the therapeutic efficacy (measured as progression-free survival) of adjuvant chemotherapy with anthracyclins is reduced in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients bearing loss-of-function alleles of TLR4 or P2RX7 </plain></SENT>
<SENT sid="3" pm="."><plain>TLR4 loss-of-function alleles also have a negative impact on the therapeutic outcome of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report that loss-of-function TLR4 and P2RX7 alleles do not affect overall survival in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) patients, irrespective of the administration and type of chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>The intrinsic characteristics of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> (which near-to-always is chemoresistant and associated with poor prognosis) and/or the type of therapy that is employed to treat this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (which near-to-always is based on <z:chebi fb="2" ids="27899">cisplatin</z:chebi>) may explain why two genes that affect the immune response to dying cells fail to influence the clinical progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> patients </plain></SENT>
</text></document>